AnHorn’s nerve-protecting drug candidate cleared for U.S. and Taiwan clinical trials (opens in new tab)

AnHorn Medicines announced in Taipei that its lead neuroprotective candidate AH-008 has received Investigational New Drug clearance from the U.S. Food and Drug Administration and Index Case designation from the Taiwan Center for Drug Evaluation. AH-008 is being developed to prevent chemotherapy-induced peripheral neuropathy, a common and dose-limiting toxicity of treatments such as taxanes, platinum-based […] The post appeared first on <a href="